At a glance
- Pexiganan is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 162 publications mentioning it, including 1 randomized controlled trial and 22 animal-only studies.
- ClinicalTrials.gov lists 4 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Adaptive Response of Escherichia coli to Pexiganan: Insights from Genomic Analysis.
- Tryptophan substitutions reveal cooperative membrane transitions and aromatic interactions associated with membrane permeabilisation in CM15 and MSI-78 peptide analogues.
- ROS/pH dual-responsive tannic acid-coated nanoparticle-integrated hyaluronic acid hydrogel for antibacterial and pro-healing effects on diabetic wounds in vitro.
- Unveiling the Potential of Magainin Derivatives against Candida Species.
- Pharmacokinetics determine persister formation in Escherichia coli.
- The discovery of novel antimicrobial peptides against multidrug-resistant bacteria based on thioether cyclization and unnatural amino acid incorporation strategies.
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.
- Comparison of agar-based and checkerboard methods to assess phage-antimicrobial synergy in Pseudomonas aeruginosa.
- Exploring immobilization strategies of antimicrobial peptides onto MAO-treated titanium to fight MRSA colonization and preserve osteogenic activity.
- Natural and Synthetic Peptides as Alternatives to Antibiotics in Intestinal Infections-A Review.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 4
- Active
- 0
- With posted results
- 2
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers | Completed | Phase 3 | Jun 2014 |
| Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers | Completed | Phase 3 | Jun 2014 |
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Completed | Phase 3 | Aug 1994 |
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers | Completed | Phase 3 | Aug 1994 |
All 4 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.